737 related articles for article (PubMed ID: 27479696)
21. Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle.
Zhang L; Keung W; Samokhvalov V; Wang W; Lopaschuk GD
Biochim Biophys Acta; 2010 Jan; 1801(1):1-22. PubMed ID: 19782765
[TBL] [Abstract][Full Text] [Related]
22. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency.
Ho KL; Zhang L; Wagg C; Al Batran R; Gopal K; Levasseur J; Leone T; Dyck JRB; Ussher JR; Muoio DM; Kelly DP; Lopaschuk GD
Cardiovasc Res; 2019 Sep; 115(11):1606-1616. PubMed ID: 30778524
[TBL] [Abstract][Full Text] [Related]
23. Myocardial fatty acid metabolism in health and disease.
Lopaschuk GD; Ussher JR; Folmes CD; Jaswal JS; Stanley WC
Physiol Rev; 2010 Jan; 90(1):207-58. PubMed ID: 20086077
[TBL] [Abstract][Full Text] [Related]
24. Cardiomyocyte-specific deletion of GCN5L1 reduces lysine acetylation and attenuates diastolic dysfunction in aged mice by improving cardiac fatty acid oxidation.
Stewart JE; Crawford JM; Mullen WE; Jacques A; Stoner MW; Scott I; Thapa D
Biochem J; 2024 Mar; 481(6):423-436. PubMed ID: 38390938
[TBL] [Abstract][Full Text] [Related]
25. Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism.
Fukushima A; Zhang L; Huqi A; Lam VH; Rawat S; Altamimi T; Wagg CS; Dhaliwal KK; Hornberger LK; Kantor PF; Rebeyka IM; Lopaschuk GD
JCI Insight; 2018 May; 3(10):. PubMed ID: 29769443
[TBL] [Abstract][Full Text] [Related]
26. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.
Zhang L; Jaswal JS; Ussher JR; Sankaralingam S; Wagg C; Zaugg M; Lopaschuk GD
Circ Heart Fail; 2013 Sep; 6(5):1039-48. PubMed ID: 23861485
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy.
Fillmore N; Mori J; Lopaschuk GD
Br J Pharmacol; 2014 Apr; 171(8):2080-90. PubMed ID: 24147975
[TBL] [Abstract][Full Text] [Related]
28. Disruption of Acetyl-Lysine Turnover in Muscle Mitochondria Promotes Insulin Resistance and Redox Stress without Overt Respiratory Dysfunction.
Williams AS; Koves TR; Davidson MT; Crown SB; Fisher-Wellman KH; Torres MJ; Draper JA; Narowski TM; Slentz DH; Lantier L; Wasserman DH; Grimsrud PA; Muoio DM
Cell Metab; 2020 Jan; 31(1):131-147.e11. PubMed ID: 31813822
[TBL] [Abstract][Full Text] [Related]
29. Metabolic abnormalities in the diabetic heart.
Lopaschuk GD
Heart Fail Rev; 2002 Apr; 7(2):149-59. PubMed ID: 11988639
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrion as a Target for Heart Failure Therapy- Role of Protein Lysine Acetylation.
Lee CF; Tian R
Circ J; 2015; 79(9):1863-70. PubMed ID: 26248514
[TBL] [Abstract][Full Text] [Related]
31. Fatty Acid Oxidation and Its Relation with Insulin Resistance and Associated Disorders.
Lopaschuk GD
Ann Nutr Metab; 2016; 68 Suppl 3():15-20. PubMed ID: 27931032
[TBL] [Abstract][Full Text] [Related]
32. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
[TBL] [Abstract][Full Text] [Related]
33. MicroRNAs in heart failure: Non-coding regulators of metabolic function.
Zhang X; Schulze PC
Biochim Biophys Acta; 2016 Dec; 1862(12):2276-2287. PubMed ID: 27544699
[TBL] [Abstract][Full Text] [Related]
34. Cardiac-specific deficiency of the mitochondrial calcium uniporter augments fatty acid oxidation and functional reserve.
Altamimi TR; Karwi QG; Uddin GM; Fukushima A; Kwong JQ; Molkentin JD; Lopaschuk GD
J Mol Cell Cardiol; 2019 Feb; 127():223-231. PubMed ID: 30615880
[TBL] [Abstract][Full Text] [Related]
35. Metabolic toxicity of the heart: insights from molecular imaging.
Iozzo P
Nutr Metab Cardiovasc Dis; 2010 Mar; 20(3):147-56. PubMed ID: 20031381
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of cardiac energetics by non-invasive
Abdurrachim D; Prompers JJ
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt B):1939-1948. PubMed ID: 29175056
[TBL] [Abstract][Full Text] [Related]
37. Targets for modulation of fatty acid oxidation in the heart.
Lopaschuk GD
Curr Opin Investig Drugs; 2004 Mar; 5(3):290-4. PubMed ID: 15083595
[TBL] [Abstract][Full Text] [Related]
38. Remodeling of substrate consumption in the murine sTAC model of heart failure.
Turer A; Altamirano F; Schiattarella GG; May H; Gillette TG; Malloy CR; Merritt ME
J Mol Cell Cardiol; 2019 Sep; 134():144-153. PubMed ID: 31340162
[TBL] [Abstract][Full Text] [Related]
39. Metabolic, structural and biochemical changes in diabetes and the development of heart failure.
Ho KL; Karwi QG; Connolly D; Pherwani S; Ketema EB; Ussher JR; Lopaschuk GD
Diabetologia; 2022 Mar; 65(3):411-423. PubMed ID: 34994805
[TBL] [Abstract][Full Text] [Related]
40. Stimulating cardiac glucose oxidation lessens the severity of heart failure in aged female mice.
Sun Q; Wagg CS; Güven B; Wei K; de Oliveira AA; Silver H; Zhang L; Vergara A; Chen B; Wong N; Wang F; Dyck JRB; Oudit GY; Lopaschuk GD
Basic Res Cardiol; 2024 Feb; 119(1):133-150. PubMed ID: 38148348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
